CTT Pharmaceutical Holdings, Inc. News Release
$CTTH
CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce The United States Patent Office has granted approval for our continuation-in-part(CIP) patent for Nicotine, Vitamins, and Caffeine utilizing our micelle delivery technology. $CTTH
CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) recieved approval from the SEC for the company's S1 and will now be an SEC reporting company. Additionally, CTT will issue a news release August 5, 2026.
CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) signs LOI with testing company for clinical trials and testing utilizing our patented technology.
CTT Pharma's PCAOB Audit for 2024 has been successfully completed. CTT has audited financials for the past 3 years.
CTT Pharma Grant Update:
CTT is expecting to get necessary information about both NIH grants on or before May 16, 2025 and the NSF grant on or before May 6, 2025. There are currently no delays. If that changes CTT will notify shareholders accordingly.
CTT will officially uplist to the OTCQB this morning. The CEO will issue a news release to shareholders Wednesday, March 12, 2025.
The OTC indicated to CTT Pharma that we will be getting more information about our uplisting to the OTCQB by early next week. CTT also found out this week that our NIH and NSF grants are not delayed.

















